Home » SANGAMO REPORTS SB-509 TRIAL DATA
SANGAMO REPORTS SB-509 TRIAL DATA
Sangamo BioSciences has announced that a Phase I human clinical trial of SB-509 or ZFP Therapeutic for the treatment of diabetic neuropathy appears to be safe and well-tolerated.
The SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA binding protein transcriptase factor. The dose-escalation study results were presented recently at the 58th Annual Meeting of the American Academy of Neurology in San Diego.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May